Enthalpic Efficiency of Ligand Binding
暂无分享,去创建一个
[1] Je Ladbury,et al. Enthalpic efficiency and the role of thermodynamic data in drug development: possibility or a pipeline dream! , 2007 .
[2] K. P. Murphy,et al. Energetics of hydrogen bonding in proteins: A model compound study , 1996, Protein science : a publication of the Protein Society.
[3] Gennady M Verkhivker,et al. Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[4] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[5] A. Schuffenhauer,et al. Complex molecules: do they add value? , 2005, Current opinion in chemical biology.
[6] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[7] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[8] Samy O Meroueh,et al. PDBcal: A Comprehensive Dataset for Receptor–Ligand Interactions with Three‐dimensional Structures and Binding Thermodynamics from Isothermal Titration Calorimetry , 2008, Chemical biology & drug design.
[9] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[10] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[11] S. Bembenek,et al. Ligand binding efficiency: trends, physical basis, and implications. , 2008, Journal of medicinal chemistry.
[12] György G Ferenczy,et al. Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.
[13] Tudor I. Oprea,et al. The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.
[14] Tudor I. Oprea,et al. Is There a Difference Between Leads and Drugs? A Historical Perspective. , 2001 .
[15] N. Powell,et al. Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. , 2007, Bioorganic & medicinal chemistry.
[16] Marcel L. Verdonk,et al. The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..
[17] Dan C. Fara,et al. Lead-like, drug-like or “Pub-like”: how different are they? , 2007, J. Comput. Aided Mol. Des..
[18] Graham F. Smith. Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. , 2009, Progress in medicinal chemistry.
[19] Heather A Carlson,et al. Differences between high- and low-affinity complexes of enzymes and nonenzymes. , 2008, Journal of medicinal chemistry.
[20] Gerhard Klebe,et al. Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.
[21] J. Willem M. Nissink,et al. Simple Size-Independent Measure of Ligand Efficiency , 2009, J. Chem. Inf. Model..
[22] N. Powell,et al. Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. , 2007, Analytical biochemistry.
[23] Richard Morphy,et al. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.
[24] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[25] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[26] Brett A Tounge,et al. The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.